ImmuCell (NASDAQ:ICCC) Releases Earnings Results, Beats Expectations By $0.16 EPS

ImmuCell (NASDAQ:ICCC) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16, FiscalAI reports. ImmuCell had a negative return on equity of 1.89% and a negative net margin of 1.82%.The firm had revenue of $10.36 million during the quarter, compared to analyst estimates of $5.40 million.

ImmuCell Stock Up 8.0%

NASDAQ ICCC traded up $0.66 on Friday, reaching $8.92. 60,599 shares of the stock traded hands, compared to its average volume of 22,428. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.93 and a current ratio of 4.26. The company has a fifty day moving average price of $7.25 and a 200-day moving average price of $6.45. The company has a market cap of $80.73 million, a price-to-earnings ratio of -148.64 and a beta of 0.50. ImmuCell has a 12 month low of $4.52 and a 12 month high of $9.08.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ImmuCell currently has an average rating of “Sell”.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC increased its stake in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,852 shares of the biotechnology company’s stock after purchasing an additional 2,907 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. 13.47% of the stock is owned by hedge funds and other institutional investors.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.